STOCK TITAN

MEI Pharma Inc - MEIP STOCK NEWS

Welcome to our dedicated news page for MEI Pharma (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEI Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEI Pharma's position in the market.

Rhea-AI Summary
MEI Pharma and Infinity Pharmaceuticals will host a joint video webcast on June 19, 2023, to provide an update on their pending merger and an overview of the combined company. The webcast will feature presentations from executive management and discussions with experts in oncology treatment. The combined company's pipeline includes three clinical-stage oncology drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
management
Rhea-AI Summary
MEI Pharma rejects unsolicited proposal from Anson Advisors Inc. and Cable Car Capital LLC to acquire all outstanding shares for $8.00 in cash per share. Board concludes proposal undervalues the Company and is not superior to pending transaction with Infinity Pharmaceuticals, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
management
-
Rhea-AI Summary
MEI Pharma confirms receipt of unsolicited proposal to acquire all outstanding shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.09%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
MEI Pharma Inc

Nasdaq:MEIP

MEIP Rankings

MEIP Stock Data

21.79M
4.94M
0.54%
47.58%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MEIP

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.